logo-loader
HealthPharma & Biotech
Admedus Ltd

Admedus COO encouraged by initial results from Phase II herpes vaccine trial

Admedus Ltd's (ASX:AHZ) chief operating officer Julian Chick talks to Proactive Investors on the interim Herpes Simplex Virus Phase II clinical trial data.

The blinded trial provided data from the first 20 patients to receive at least three vaccinations in the randomised, placebo–controlled HSV-2 vaccine Phase II study.

Chick says he is “very encouraged” by the first set of results, which shows the study is “going in the right way and we are seeing what we want to see”.

Quick facts: Admedus Ltd

Price: $0.06

Market: ASX
Market Cap: $35.4 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read